deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02501928

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047

Sponsor: Pfizer

Conditions Urinary Bladder, Neurogenic
Interventions Fesoterodine BIC 2 mg Fesoterodine BIC 4 mg Fesoterodine PR 4 mg Fesoterodine PR 8 mg
Updated 22 times since 2017 Last updated: Nov 25, 2020 Started: Jun 5, 2015 Primary completion: Apr 1, 2020 Completion: Apr 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Urinary Bladder, Neurogenic and is currently completed. Pfizer leads this study, which shows 22 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 17 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Nov 2020 — Dec 2020 [monthly]

    Completed PHASE3

  3. Sep 2020 — Nov 2020 [monthly]

    Completed PHASE3

  4. Jun 2020 — Sep 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE3

  7. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  8. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  9. Nov 2018 — Aug 2019 [monthly]

    Recruiting PHASE3

  10. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  11. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  13. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  14. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  15. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  16. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  17. Jan 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations